Literature DB >> 9609211

Obesity: a never-ending cycle?

J P Foreyt1, W S Poston.   

Abstract

Obesity is the number one public health concern in the United States, affecting over one-third of women. Minorities are at highest risk, with nearly 50% of African-American and Mexican-American women obese. Obesity significantly increases risk for mortality and morbidity in women, including several gynecological and reproductive disorders and infertility. Obesity, with the resultant hyperinsulinemia and hyperandrogenemia, negatively affects normal menstrual function and fertility. In addition, maternal adiposity may increase risk in offspring through perinatal mechanisms, resulting in a never-ending cycle of obesity. Data suggest that modest weight losses of about 10% of initial weight are effective in improving hormonal profiles, menstrual regularity, ovulation, and pregnancy rates. Available treatments include life-style modification programs, with a focus on eating a healthful diet and increasing physical activity, plus adjunctive pharmacotherapies.

Entities:  

Mesh:

Year:  1998        PMID: 9609211

Source DB:  PubMed          Journal:  Int J Fertil Womens Med        ISSN: 1534-892X


  3 in total

1.  Obesity, polycystic ovary syndrome, infertility treatment: lifestyle modification is paramount.

Authors:  Jonathan M Lord; Robert Norman
Journal:  BMJ       Date:  2006-03-11

2.  CREB activation induces adipogenesis in 3T3-L1 cells.

Authors:  J E Reusch; L A Colton; D J Klemm
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  ACTonHEALTH study protocol: promoting psychological flexibility with activity tracker and mHealth tools to foster healthful lifestyle for obesity and other chronic health conditions.

Authors:  Roberto Cattivelli; Gianluca Castelnuovo; Alessandro Musetti; Giorgia Varallo; Chiara A M Spatola; Francesco Vailati Riboni; Anna Guerrini Usubini; Fabio Tosolin; Gian Mauro Manzoni; Paolo Capodaglio; Alessandro Rossi; Giada Pietrabissa; Enrico Molinari
Journal:  Trials       Date:  2018-11-29       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.